Raymond James & Associates Unity Biotechnology, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Apr 21, 2020
SELL
$5.0 - $7.6 $263,725 - $400,862
-52,745 Closed
0 $0
Q4 2019

Feb 12, 2020
BUY
$5.99 - $8.38 $315,942 - $442,003
52,745 New
52,745 $380,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0
View Full List

About Unity Biotechnology, Inc.

UBX Quotes by TradingView
  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $25.7M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email